Q3 Earnings Estimate for ClearPoint Neuro Issued By B. Riley

Key Points

• B. Riley has revised its Q3 2025 earnings per share (EPS) estimate for ClearPoint Neuro from ($0.17) to ($0.20), with the overall consensus for the current fiscal year at ($0.66) EPS.
• ClearPoint Neuro reported a Q2 earnings miss with an EPS of ($0.21), failing to meet the consensus estimate of ($0.20), alongside a significant net margin of 66.15% and return on equity of 94.44%.
• Insider trading activity includes sales by Director Timothy T. Richards and CEO Joseph Burnett, with both reducing their holdings by approximately 11.44% and 8.02% respectively.

ClearPoint Neuro, Inc. (NASDAQ:CLPT - Free Report) - B. Riley cut their Q3 2025 EPS estimates for ClearPoint Neuro in a research note issued to investors on Tuesday, August 12th. B. Riley analyst A. Schock now forecasts that the company will post earnings per share of ($0.20) for the quarter, down from their prior forecast of ($0.17). The consensus estimate for ClearPoint Neuro's current full-year earnings is ($0.66) per share. B. Riley also issued estimates for ClearPoint Neuro's Q4 2025 earnings at ($0.19) EPS, FY2025 earnings at ($0.81) EPS, Q1 2026 earnings at ($0.19) EPS, Q2 2026 earnings at ($0.18) EPS, Q3 2026 earnings at ($0.16) EPS, Q4 2026 earnings at ($0.14) EPS and FY2026 earnings at ($0.67) EPS.

ClearPoint Neuro (NASDAQ:CLPT - Get Free Report) last issued its quarterly earnings data on Tuesday, August 12th. The company reported ($0.21) earnings per share for the quarter, missing the consensus estimate of ($0.20) by ($0.01). ClearPoint Neuro had a negative return on equity of 94.44% and a negative net margin of 66.15%.The company had revenue of $9.22 million for the quarter, compared to analysts' expectations of $9.20 million. ClearPoint Neuro has set its FY 2025 guidance at EPS.

Other equities research analysts have also recently issued reports about the company. Wall Street Zen cut ClearPoint Neuro from a "hold" rating to a "sell" rating in a research note on Saturday, July 12th. Stifel Nicolaus upped their target price on ClearPoint Neuro from $8.00 to $9.00 and gave the company a "buy" rating in a research note on Friday, August 1st. Three research analysts have rated the stock with a Buy rating, Based on data from MarketBeat, ClearPoint Neuro has a consensus rating of "Buy" and a consensus target price of $19.67.

ClearPoint Neuro Trading Down 6.8%

CLPT traded down $0.76 on Friday, reaching $10.46. 415,130 shares of the company's stock were exchanged, compared to its average volume of 318,394. The company's 50 day moving average is $11.38 and its 200-day moving average is $12.97. The company has a market cap of $297.38 million, a price-to-earnings ratio of -12.91 and a beta of 0.85. ClearPoint Neuro has a twelve month low of $9.76 and a twelve month high of $19.22. The company has a debt-to-equity ratio of 1.46, a quick ratio of 6.45 and a current ratio of 7.30.

Institutional Investors Weigh In On ClearPoint Neuro

A number of institutional investors and hedge funds have recently bought and sold shares of the company. Millennium Management LLC lifted its holdings in shares of ClearPoint Neuro by 156.3% in the 1st quarter. Millennium Management LLC now owns 741,193 shares of the company's stock valued at $8,813,000 after buying an additional 452,043 shares during the period. Geode Capital Management LLC increased its holdings in shares of ClearPoint Neuro by 107.3% in the second quarter. Geode Capital Management LLC now owns 624,800 shares of the company's stock valued at $7,461,000 after purchasing an additional 323,429 shares during the last quarter. Invesco Ltd. purchased a new position in shares of ClearPoint Neuro during the fourth quarter worth $3,814,000. Goldman Sachs Group Inc. boosted its holdings in ClearPoint Neuro by 98.3% in the first quarter. Goldman Sachs Group Inc. now owns 257,871 shares of the company's stock valued at $3,066,000 after purchasing an additional 127,823 shares during the period. Finally, Jane Street Group LLC raised its stake in ClearPoint Neuro by 119.6% in the fourth quarter. Jane Street Group LLC now owns 222,307 shares of the company's stock valued at $3,419,000 after buying an additional 121,083 shares in the last quarter. 30.08% of the stock is owned by institutional investors.

Insider Activity at ClearPoint Neuro

In related news, Director Timothy T. Richards sold 10,000 shares of ClearPoint Neuro stock in a transaction that occurred on Tuesday, June 10th. The stock was sold at an average price of $13.28, for a total transaction of $132,800.00. Following the sale, the director directly owned 77,381 shares in the company, valued at $1,027,619.68. The trade was a 11.44% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Joseph Burnett sold 21,247 shares of the company's stock in a transaction on Monday, June 9th. The shares were sold at an average price of $13.29, for a total value of $282,372.63. Following the sale, the chief executive officer owned 243,522 shares of the company's stock, valued at approximately $3,236,407.38. This trade represents a 8.02% decrease in their position. The disclosure for this sale can be found here. 6.11% of the stock is currently owned by insiders.

About ClearPoint Neuro

ClearPoint Neuro, Inc operates as a medical device company primarily in the United States. It develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under magnetic resonance imaging guided interventions. The company offers ClearPoint system, an integrated system for the insertion of deep brain stimulation electrodes, biopsy needles, and laser catheters, as well as the infusion of pharmaceuticals into the brain.